<DOC>
	<DOCNO>NCT00004753</DOCNO>
	<brief_summary>OBJECTIVES : I. Correlate clinical outcome cerebral glucose metabolism patient Huntington 's disease ( HD ) at-risk relative . II . Evaluate efficacy cerebral glucose metabolism observe pathophysiologic development HD , monitoring response experimental therapy , predict HD genotype . III . Identify , define , describe natural history pathophysiologic lesion HD . IV . Characterize genotypic phenotypic expression HD gene .</brief_summary>
	<brief_title>Long-Term Study Cerebral Glucose Metabolism Huntington 's Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Participants screen Huntington 's disease , include cerebral glucose metabolism assessment genetic testing . Studies include detailed family history neurologic , psychometric , neurobehavioral evaluation . Imaging include positron emission tomography fluorodeoxyglucose brain magnetic resonance imaging . A genotype assessment perform ; genetic result disclose patient relative .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Documented family history Huntington 's disease ( HD ) Symptomatic HD : chorea require Atrisk HD : detectable systemic oculomotor abnormality Agematched control subject No history inherit neurological disease No general neurologic abnormality Prior/Concurrent Therapy At least 4 week since HD treatment , e.g . : Haloperidol Benzodiazepine Other tranquilizer neuroleptic Patient Characteristics No pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>Huntington 's disease</keyword>
	<keyword>neurologic psychiatric disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>